Peptide PilotPeptide Pilot

mg ↔ units

GHRP-2 mg to units converter

Set your GHRP-2 vial concentration once, then flip in either direction between milligrams and U-100 syringe units.

Download Peptide PilotiPhone · Free to download

mg

0.100

units

4.00

mL

0.040

Concentration: 2.50 mg/mL (assumes a U-100 insulin syringe).

GHRP-2 is a short-acting injectable peptide people use to trigger sharp pulses of their own growth hormone, usually paired with a GHRH like CJC-1295 or sermorelin. It mimics ghrelin at the GH-secretagogue receptor, producing a strong but brief GH spike within minutes of injection. Published studies show clear post-injection GH peaks, with some appetite increase as a side effect. This page covers reconstitution math and per-injection logging cadence.

How the GHRP-2 mg ↔ units converter works

This converter is a two-way bridge between dose mass (mg or mcg) and the unit count you actually draw on an insulin syringe. Once you set the GHRP-2 concentration of your current vial, you can type any mg value and read the units back, or type any unit count and read the mg back. It is the same math as the dose calculator, but bidirectional, which matters when you are checking a dose someone else recorded in units against a protocol written in mg.

The formula in both directions: mg = mL × concentration mg/mL, and units = mL × 100 on a U-100 syringe. With a 2.5 mg/mL GHRP-2 solution, 0.1 mg comes out to 4 units, and 4 units comes out to 0.1 mg. The converter handles the unit flip automatically so you never multiply or divide in your head while holding a syringe.

Concentration is the input that changes the answer most. A 5 mg vial diluted with 1 mL is twice as concentrated as the same vial diluted with 2 mL, which means the same dose draws half as many units. That is the single biggest source of converter confusion: a remembered unit count from an old vial does not transfer to a new vial reconstituted with different water volume.

Use the converter whenever a protocol or research note is written in one unit and your syringe is labeled in the other. It is also useful for sanity-checking that a planned titration step lands at a unit count you can read accurately on the syringe — under five units gets hard to read, over fifty starts crowding into the back third of a 1 mL syringe.

Why this matters for GHRP-2

GHRP-2 (D-Ala-D-2-Nal-D-Trp-D-Phe-Lys-NH2) occupies a unique position as a second-generation ghrelin agonist, developed in the 1990s as a successor to the first-generation GHRP-6. Its a hexapeptide structure, modified from its predecessor, was engineered to provide greater selectivity for the growth hormone secretagogue receptor (GHSR-1a). This structural distinction is the basis for its characterization as a middle-ground compound within its family. Published research indicates that this increased selectivity translates to a different side-effect signature when compared directly to GHRP-6, particularly concerning the potentiation of hunger and elevation of prolactin and cortisol.

While more selective than GHRP-6, GHRP-2 is understood to be less selective than the later-developed peptide, ipamorelin, which exhibits a more targeted action on GH release. The practical consequence of GHRP-2's properties, including its short biological half-life, is the frequent documentation of protocols involving one to three administrations per day. This high-frequency cadence creates a significant challenge for accurate personal record-keeping, a problem that a detail-oriented calculator and logging application is designed to solve by systematically documenting dose, concentration, and time of day for every entry.

GHRP-2 mechanism in plain English

GHRP-2 functions as an agonist of the growth hormone secretagogue receptor, type 1a (GHSR-1a), the same receptor targeted by the endogenous hormone ghrelin. Although it shares this primary mechanism with its predecessor, GHRP-6, its modified hexapeptide structure alters its binding characteristics and subsequent intracellular signaling. The substitution of a D-Alanine residue is a key factor in this functional difference. This distinction in receptor interaction is what underlies the observed differences noted in comparative literature, where GHRP-2 often produces a strong GH pulse with a reduced propensity for stimulating the intense hunger response sometimes associated with GHRP-6. The compound's action is entirely mediated through the ghrelin receptor pathway, a separate mechanism from that of GHRH and its analogs.

Tracking GHRP-2 unit counts

For GHRP-2, the single most critical variable to log is the exact time of each administration. Due to study protocols that often involve a one-to-three times daily cadence, a simple dose-and-date entry is insufficient for any form of retrospective analysis. Without a precise timestamp, it becomes impossible to differentiate the effects of a morning dose from a pre-bed dose or analyze how timing relative to meals or other activities might correlate with logged observations. Therefore, meticulously stamping every dose with the hour and minute is paramount to creating a dataset that retains its analytical value over time.

Common GHRP-2 conversion mistakes

  • Mistaking GHRP-2 for GHRP-6 and failing to account for the documented differences in their side-effect profiles regarding appetite stimulation and prolactin.
  • Neglecting to log the specific time of day for each dose in a multi-dose schedule, which renders later analysis of the data almost meaningless.
  • Using a large-volume syringe (e.g., a 3 mL syringe) that lacks the fine gradations needed to accurately measure a typical 100 mcg dose volume.
  • Administering a dose immediately following a large meal, a variable noted in research that can interfere with the peptide's primary action.
  • Basing dose calculations on a previous vial's concentration without verifying the milligram amount and diluent volume for the new vial.

Frequently asked questions about GHRP-2 mg ↔ units

How is GHRP-2 structurally different from GHRP-6?
GHRP-2 is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-D-Trp-D-Phe-Lys-NH2. It was developed as a second-generation evolution of GHRP-6. The primary structural difference is the substitution of the natural L-Alanine found in GHRP-6 with a synthetic D-Alanine residue. This single amino acid change significantly alters the molecule’s interaction with the ghrelin receptor, giving rise to its different selectivity profile.
Why do studies describe GHRP-2 as more selective than GHRP-6?
In comparative scientific studies, GHRP-2 has been observed to stimulate a potent release of growth hormone while having a lesser impact on cortisol, prolactin, and appetite compared to dose-equivalent administrations of GHRP-6. This means its action is more focused on GH release. While it targets the same ghrelin receptor, its modified structure results in this more specific downstream effect, though it is still considered less selective than the third-generation peptide ipamorelin.
If a 5 mg vial of GHRP-2 is reconstituted with 2 mL of water, how many units are drawn for a 100 mcg dose?
When a 5 mg (5,000 mcg) vial is reconstituted with 2 mL of diluent, the final concentration becomes 2,500 mcg per mL. To calculate the volume for a 100 mcg dose, you divide the dose by the concentration: 100 mcg ÷ 2,500 mcg/mL equals 0.04 mL. On a U-100 insulin syringe, 0.04 mL corresponds to exactly 4 units.
What is the rationale for the multiple daily administrations sometimes seen in research logs?
Like other peptides in the ghrelin mimetic class, GHRP-2 has a very short biological half-life, meaning its action dissipates quickly after administration. To study the effect of more sustained GH elevation, research protocols often involve scheduling multiple smaller doses throughout the day. This approach contrasts with using a single, larger dose, which would produce a more acute but less frequent pulse.
Why is it so important to log the time of day when documenting a GHRP-2 protocol?
Because study protocols can involve one, two, or three administrations per day, a log entry that only states the date and dose amount is incomplete. A timestamp clarifies if it was a morning dose on an empty stomach, a pre-workout dose, or a pre-bedtime dose. This granular detail is crucial for any meaningful retrospective analysis, as the timing of administration relative to other factors like meals is a key variable.
Does GHRP-2 work through the same mechanism as a GHRH analog like Sermorelin?
No, they operate via completely separate and distinct pathways. GHRP-2 is a ghrelin receptor agonist, mimicking the hormone ghrelin to stimulate the pituitary gland through the GHSR-1a receptor. In contrast, GHRH analogs like Sermorelin work by binding to the Growth Hormone-Releasing Hormone receptor (GHRHR). While both pathways ultimately lead to GH release, they are independent mechanisms.

Related on Peptide Pilot

Save your GHRP-2 vial in the app

Download on the App Store
Get the App